NCT00430846View on ClinicalTrials.gov

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Lymphoma, Non-HodgkinDisease, HodgkinLymphoma, Large-Cell, Anaplastic
Interventions
DRUG

SGN-35

Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg

Trial Locations (4)

10021

Weill Cornell Medical College, New York

35294

University of Alabama at Birmingham, Birmingham

63110

Washington University, St Louis

77030

University of Texas/MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT00430846 - Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | Biotech Hunter | Biotech Hunter